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Alzheimer’s disease (AD) is the most common neurodegenerative disease among the elderly with a 
progressive decline in cognitive function significantly affecting quality of life. Both the prevalence 
and emotional and financial burdens of AD on patients, their families, and society are predicted to 
grow significantly in the near future, due to a prolongation of the lifespan. Several lines of evidence 
suggest that modifications of risk-enhancing life styles and initiation of pharmacological and non-
pharmacological treatments in the early stage of disease, although not able to modify its course, 
helps to maintain personal autonomy in daily activities and significantly reduces the total costs of 
disease management. Moreover, many clinical trials with potentially disease-modifying drugs are 
devoted to prodromal stages of AD. Thus, the identification of markers of conversion from 
prodromal form to clinically AD may be crucial for developing strategies of early interventions.  
The current available markers, including volumetric MRI, PET, and CSF analysis are expensive, 
poorly available in community health facilities, and relatively invasive. Taking into account its low 
cost, widespread availability and non-invasiveness, EEG would represent a candidate for tracking 
the prodromal phases of cognitive decline in routine clinical settings eventually in combination with 
other markers. After providing a short overview of the epidemiology andmarkers in AD, this review 
aimed to explore whether advanced analysis of EEG rhythms exploring brain function has sufficient 
specificity/sensitivity/accuracy to screen out the risk of conversion from Mild cognitive Impairment 





This review describes an integrated and multidisciplinary approach for the “early” diagnosis of AD. 
An overview of epidemiology, genetic risk factors, and different biomarkers of AD is provided.  
Analysis of EEG rhythms could represent a valid screening tool to predict AD conversion.  
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Alzheimer's disease (AD) is characterized by a progressive loss of memory and deterioration of 
other cognitive functions. The typical AD clinical phenotype follows a prodromal stage known as 
Mild Cognitive Impairment (MCI), usually characterized by memory loss (amnestic MCI= aMCI), 
which includes a consistent percentage (about 50%) of subjects in a stage prodromal to dementia 
(aMCI usually to AD). The identification of reliable markers able to intercept those aMCI who are 
in a prodromal stage may allow for developing early interventions. In fact, even in the absence of a 
disease-modifying therapy, several lines of evidence suggest that early initiation of pharmacological 
and non-pharmacological treatments (including changes in lifestyle) helps maintain personal 
autonomy in daily activities and significantly reduces the total costs of disease management 
(D’Amelio and Rossini, 2012; Teipel et al., 2015; Petersen et al., 2017). Moreover, many of the 
clinical trials with potentially disease-modifying drugs target MCI prodromal-to-AD subjects, since 
failure has been demonstrated when full symptomatology of AD has been already developed. 
Therefore, early markers predicting with high sensitivity/specificity the evolution from prodromal 
stages to clinically overt AD are of pivotal importance. Although this goal can be partly reached 
with the presently available diagnostic armamentarium (volumetric MRI, PET, 
PET+radioligands/Lumbar puncture for amyloid and tau metabolites), all of these markers have a 
relatively low sensitivity to synaptic dysfunction (the very early stage of presymptomatic AD); 
moreover, most of them are expensive, poorly available on community health facilities and 
relatively invasive. Taking into account its low cost, widespread availability and non-invasiveness, 
electroencephalographic signals (EEG) analysis may be an excellent candidate for tracking the 
prodromal phases of cognitive decline in routine clinical settings. This review paper was prepared 
under the endorsement of the International Federation of Clinical Neurophysiology (IFCN) and is 
the result of an “Experts Workshop” held in Rome in June 2017. Its goal is to provide an overview 
of the epidemiology and genetic risk factors as well as of neuropsychological and neuroimaging 
biomarkers, but is particularly aimed to understand whether advanced analysis of EEG rhythms 
exploring brain function has sufficient specificity/sensitivity/accuracy to screen out the risk of 
conversion from MCI to AD as a first-level screening method. 
 
2. Alzheimer’s Epidemiology 
The AD phenotype and syndrome classification has improved substantially over the last decade. 
The diagnosis in the preclinical phase is based largely on limited and selected data from few tertiary 
centers. There are few and limited population–based data on the issues of new classification 
systems and diagnosis anticipation. Population-based data with the use of new, including advanced 
markers, and old criteria originate from the Mayo Clinic Study on Aging  (MCAS) as part of the 
study of the Rochester Epidemiologic Project (REP; Rocca et al., 2018). 
In everyday clinical activity the prompt diagnosis of dementia is missed in a large number of cases 
using the old NINCDS-ADRDA criteria (Rait et al., 2010). This is evident comparing data from the 
active search in population-based studies as CFAS and EURODEM with data from files of the GPs 
of the national UK database (passive ascertainment based on referral). The misdiagnosis or missed 
diagnosis is much larger in the >80 age groups compared with lower age groups. This is relevant 
considering that two out of three patients with AD will be over age 85 by 2050. One of the most 
interesting questions is the time trend of dementia incidence. Dementia prevalence is steadily 
growing, caused both by the aging and increased life expectation of the general population. This is a 
worldwide phenomenon. China, India, Indonesia and Brazil drive these demographic changes as a 
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result of the huge size of their population (Logroscino, 2017). Recent prevalence data from CFAS 
in the elderly population (older than 65) from six geographic areas in England and Wales show that 
dementia prevalence estimated in the period 2008-11 was almost 25% less than what was predicted 
based on prevalence data estimated in the period 1989-94, in the same area (Matthews et al., 2013).  
Consistently, CAFS report a drop in incidence of about 20%, mainly determined by a decline in 
incidence among males (Matthews et al., 2016). 
Similarly, in the Framingham Study a population-based investigation (Satizabal et al., 2016) has 
been conducted looking at dementia incidence time trends in five thousands elderly (more than 60) 
within the period 1977-2008, divided in four 5-year intervals. The cumulative dementia incidence 
rates declined from 3.6 / 100 to 2.0 per / 100 person year. Dementia declined about 44% in the more 
recent period only in subjects with at least high school diploma. The decline was both for AD and 
vascular dementia. In the same period, there was an increase in diabetes, obesity and hypertension. 
On the other side, there was an increase in number of hypertensive subjects with medical treatment, 
a reduction of stroke), a decrease in the prevalence of smoking, an increase of average levels of 
high-density lipoprotein (HDL) cholesterol. Furthermore, there was really a dramatic increase in 
education, with subjects holding a college degree going from 13 to 34 %. Several causes and 
possible interactions of these changes have still to be identified. 
All these evidences show that –under appropriate lifestyle modifications– dementia incidence is 
declining in a relatively short period of time, similarly to what happened previously for myocardial 
infarction and stroke (Mozaffarian et al., 2015). These changes indicate that dementia is largely 
preventable. In the last two decades, several observational studies have shown a wide variety of 
potentially modifiable risk factors for cognitive impairment and dementia (Livingston et al., 2017), 
which have been proposed as targets for preventive strategies. In addition to cardiovascular risk 
factors, psychological conditions, education level, engagement in social and mentally stimulating 
activities, sensory changes, and lifestyle including diet, physical activity and voluptuary habits has 
obtained a crucial role (Panza et al., 2015; Livingston et al., 2017). The recognition of modifiable 
risk factors and successive intervention may be part of a population strategy that could lead to a 
significant decrease of about 30% of dementia cases, according to conservative estimates recently 
published (Norton et al., 2014).  
 
3. Cost effectiveness of early diagnosis in Alzheimer’s disease 
AD was estimated in 2010 to cost about $604 billion in US annually. These costs are staggering, 
particularly taking into account the predictions for the growth in the worldwide number of AD cases 
(Wimo et al., 2013) will increase rapidly in the next decades. The global costs of dementia were 
estimated in the United States (US) to total $818 billion in 2015, an increase of 35% since 2010; 
86% of the expenses are incurred in high-income countries. The costs of informal care and the 
direct costs of social care still contribute within similar proportions the total cost, whereas the cost 
of the medical sector is much lower. The threshold of US $1 trillion is currently being crossed 
(Wimo et al., 2017). The advantage for an early diagnosis of AD in a scenario that does not permit 
disease modifying therapy is still debated and, in absence of such therapies, programs devoted to 
screen general old population for AD could appear useless. In contrast, it is generally thought that 
also the treatment with Choline Esterase inhibitors (ChEi) is more effective when used before 
widespread pathological changes have occurred (Cummings JL et al., 2008; Hogan et al., 2008).  
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On this field, several neuroeconomic investigations have provided reliable recommendation about 
the effect of an early diagnosis on the social cost and the advantage in patient management. In 
particular, timely detection and symptomatic intervention in AD-dementia can be cost-effective 
because even though having limited efficacy, they nonetheless control symptoms enough to reduce 
healthcare costs and keep patients living longer in the community (Geldmacher, 2008). Moreover, a 
UK study based on 2007 costs estimated that cover ten years, timely detection and treatment 
produced savings of £3600 (US $5508) in direct costs and an additional £4150 ($6350) in indirect 
costs (caregiver time) per patient (Getsios D et al., 2012). 
Despite the burden posed on individuals and the health care system, diagnosis of AD is clearly 
suboptimal. For instance, the UK National Audit Office estimates that more than half of all cases of 
AD in the United Kingdom are undiagnosed.  
Recently, Barnett and coworkers (2014) explored the effect of an early diagnosis and interventions 
in the Paquid cohort. They calculated the economic effects of moving AD diagnosis from the real 
standard diagnosis (MMSE 18) to the previous 8 years.  They applied a statistical model in which a 
symptomatic treatment that improve cognition by one MMSE point would produce a maximum net 
cost benefit when applied at the earliest time point and this effect would drop 17% for each year of 
delayed diagnosis. In contrast, for a scenario where a disease-modifying treatment (DMT) halting 
cognitive decline for one year, economic benefits would peak when treatment effects were applied 
two years prior to standard diagnosis. In this case the effect would be fifteen times greater than in 
the symptomatic one. It’s clear that the modification of the clinical trajectories with both 
symptomatic and DMT could have enormous consequences on the general cost of AD management. 
This offers a challenge for all Health Services, which should be prepared to face an increasing 
number of subjects with dementia. Besides, when we pass to the scenario of DMT availability, the 
diagnosis will move from AD-dementia to pre-dementia AD states. In such condition, clinical 
criteria are unlikely to be appropriate and progressively more expensive investigations will be 
required.  
 
4. Overwiew on AD Markers 
The role of markers in the diagnosis of dementia is becoming progressively more important as the 
need for an “early” diagnosis is now prominent, namely a diagnosis in pauci- or asymptomatic 
disease stages. The concept of “MCI prodromal to AD” has been introduced in a manuscript from a 
panel of international experts (Dubois et al., 2010, 2014), showing that if neuropsychological tests 
are combined with information from neuroimaging (both structural and flow/metabolic), CSF 
analysis and genetic risk evaluation, one can predict with high accuracy the evolution to AD in MCI 
subjects at an individual basis or –better– MCI subjects who are already in a stage prodromal to AD 
can be promptly intercepted. 
The main criterion for quality selection in this review has been focused on those markers best 
predicting the progression from MCI to AD in longitudinal studies, while cross-trans-sectional 
studies were excluded. When looking to the best evidences for each biomarker, Cochrane reviews 
which identify quality of the studies by means of the checklist QUADAS (Quality Assessment of 
Diagnostic Accuracy Studies) and STARD (Standards for Reporting Diagnostic Accuracy) were 





Subjects with a prodromal stage of AD (IWG2) or Mild cognitive impairment (MCI) prodromal-to-
AD (NIA-AA) are the main targets for the employment of diagnostic/prognostic markers. MCI is a 
clinical and neuropsychological state in the elderly brain intermediate between normal cognition 
and dementia. It is mainly characterized by objective evidence of memory impairment during a 
neuropsychological examination that does not yet encompass the definition of dementia. 
Epidemiological research suggests that aMCI is a precursor of AD, based on the high rate of 
progression from this state to AD. Not all MCI subjects convert to dementia, but many, between 50 
and 60%, do it. The remaining individuals will either remain in the MCI condition or return to a 
fully normal one and never progress to dementia. To plan optimal and early therapeutic, 
organizational and rehabilitative interventions, aMCI diagnosis should be combined with the most 
reliable prognosis on the likelihood and time of progression to dementia. The MCI definition 
requires the following: cognitive questionnaire, screening tests (MMSE), neuropsychological 
evaluation - including 2 tests for episodic memory, tests for language, visuo-spatial abilities and 
behavioral scales with appropriate normative thresholds (Cerami et al., 2017; Costa et al., 2017) -, 
functional scales, neurological examination and a CDR score of 0.5. Growing evidences suggest 
that early diagnosis reduces health and social costs for dementia management. Moreover, MCI 
prodromal to AD is becoming progressively more frequent and is the preferred target for clinical 
trials with potential disease-modifying experimental drugs. Early diagnosis of the MCI prodromal 
to AD can presently be reached with a very high sensitivity and specificity by combining a number 
of tests (i.e. hippocampal volumetric MRI, 18F-FDG PET and lumbar puncture for CSF 
examination). Because of their elevated costs, low availability and/or invasiveness, though, these 
cannot be applied to evaluate a large population sample on a nationwide scale. In a recent study by 
an international consortium (Cohort Studies Memory in an International Consortium-COSMIC - 
Sachdev et al., 2015) it was attempted to define the epidemiological boundaries of the MCI 
condition by a metanalysis of the published data. A prevalence of 5.9% has been estimated in a 
population with >60 year, with an increment of the stratified age ranges from 4.5% (60 to 69 years), 
to 5.8% (70 to 79 years) and 7.1% (80 to 89 years). On this basis, - even if this scenario is not 
accepted by all the Experts (see Petersen et al., 2018) - just for example, for the 2016 in European 
Community population an estimated number of about 8.000.000 MCI subjects can be predicted.   
	
4.1 Genetic markers  
Three decades of genetic research have substantially broadened our knowledge about pathogenic 
mechanisms leading to neurodegeneration and dementia, starting, however, from very rare forms of 
AD. In the 20th century, genetic linkage analysis identified three major causes underlying 
genetically dominant early onset forms of AD (ADAD) such as Amyloid precursor protein (APP), 
and Presenilins (PSEN1 and PSEN2) genes (Goate et al., 1991; Levy-Lahad et al., 1995; 
Sherrington et al., 1995).  Mutations of these genes represent state markers of the disease, since 
they are dominant mutations, carriers develop and transmit the disease to 50% of offspring, and 
penetrance is about 100%. Although ADAD has a rather clear phenotype characterized by memory 
loss, time and space confusion, apraxia, agnosia, troubles of language, neither the onset nor the 
phenotype are constant and monomorphic, and overlapping can be frequently observed between 
clinical phenotypes, genotypes and also pathological proteotypes (Tang et al., 2016). Several 
families carrying a PSEN1 mutation have been described with involvement of frontal lobe or spastic 
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paraplegia (Piscopo et al., 2008; Wallon et al., 2012) or extrapyramidal signs thus mimicking Lewy 
body dementia (Karlstrom et al., 2008; Wallon et al., 2012). Even in the large ADAD Calabrian 
kindreds, sharing the same PSEN1 mutation and a classic neuropathological phenotype, at onset 
symptoms cluster into four different groups: apathetic, amnesic, dysexecutive, disoriented (Bruni et 
al., 2010) (Fig. 1A). The APP A713T mutation leading to AD with cerebrovascular lesions (CVLs) 
in Calabrian families associates to both early and late onset phenotypes, also independently from 
homozygosity (Conidi et al., 2015) (Fig. 1B).  
The multigenerational ADAD families (Tang et al., 2016) frequently reconstructed along centuries 
through genealogy with hundreds of affected subjects and at risk relatives represent an 
extraordinary and powerful model for the study of AD. All the three genes are involved in the 
processing of beta amyloid strongly sustain the amyloid cascade hypothesis (Schellenberg and 
Montine, 2012). DIAN cohort constituted by ADAD carriers has already showed that the biological 
disease starts in the brains decades before clinical onset (Tang et al., 2016) with the deposition of β 
amyloid and the alterations of the other biomarkers. The same certitude cannot be confirmed in late 
onset AD that is still unclear regarding etiology and pathogenesis and whose genetic component is 
complex and much more difficult to ascertain. 
The lifetime risk to develop AD is about 10-12% (Breitner et al., 1999) and a genetic susceptibility 
increasing or decreasing the risk of developing the disease does exist. There are almost an infinite 
number of susceptibility genes for dementia. The Apolipoprotein E (APOE) gene with the e4 allele 
gives to carriers a higher risk of developing the disease, especially in women (Liu et al., 2013), 
shortening of the age of onset of AD not only in sporadic AD patients but also in carriers of 
mutations of both the PSEN1 (Pastor et al., 2003) and of APP (Sorbi et al., 1995). In recent years 
several whole-genome sequencing studies (GWAS) have suggested that the risk of developing AD 
is given by the association of common polymorphisms with low penetrance and high frequency in 
the population and, therefore, with small effect size; although the total number of AD risk genes 
remains elusive there are significant evidences suggesting that their combinations may have a 
substantial impact on disease susceptibility, onset (Bertram and Tanzi, 2008) and progression of 
sporadic LOAD.  
Theoretically, assessment of genetic risk could be a key to preventing or slowing the progression of 
the Alzheimer’s disease. APOE ε4 genotype has been demonstrated as the major predictor of 
progression to AD in patients with aMCI (Zheng et al., 2016). However, the use of APOE 
genotyping is limited due to its low sensitivity and specificity, but it could be useful in combination 
with other markers including EEG connectivity (Vecchio et al 2018). Zheng et al. (2016) found a 
notable increase in plasma homocysteine (HCY) together with a significant decrease in serum 
brain-derived neurotrophic factor (BDNF) in aMCI - APOE ε4 patients converting to AD. Studies 
focused on changes in DNA methylation level (i.e. COASY and SPINT1 gene promoter regions) 
could be helpful to identify subjects destined to progress from MCI to AD (Kobayashi et al., 2016).  
Although ADAD mutations are marker of state not of process, combined together with current 
biomarkers, they will allow an early diagnosis even in the preclinical phase. The implementation 
and evaluation of AD genetic risk markers in the prediction of MCI to AD dementia progression it 
is in an early phase. However, detecting new susceptibility factors with a functional impact on AD 
will bring about major insights into the disease pathways, and initiate new lines of research.  
 
4.2 Neuropsychological markers 
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An important milestone for the modern era of AD research is the publication of the NINCDS-
ADRDA clinical criteria for the diagnosis of Alzheimer’s dementia, which remained the standard 
reference in the field for more than two decades (McKhann et al., 1984). According to the original 
McKhann criteria, “neuropsychological tests provide confirmatory evidence of the diagnosis of 
dementia and help to assess the course and response to therapy”. Neuropsychological tests are 
recommended for specific aims, such as the definition of unusual pattern of cognitive deficits, in the 
context of longitudinal studies or as outcome measures for drug efficacy trials. An important change 
took place only in the ‘90s, with the rise of interest in the identification of a “pre-dementia” stage of 
AD, resulting in the introduction of the MCI concept (Petersen et al., 1999). Among the criteria for 
the diagnosis of this at-risk condition for progression to dementia is the presence of an objective 
impairment of memory, defined on the basis of a defective test performance in comparison to an 
age-matched control group. In the following period this concept was extended, on the basis of the 
same psychometric criteria, to other cognitive domains besides long-term memory (Petersen, 2004).  
The International Working Group Research Criteria (Dubois et al., 2007, 2010, 2014) and the 
National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines 
(McKhann et al., 2011) introduced a novel approach, based on the concept of an AD continuum, 
rather than of disease “stages”. Both set of criteria emphasize the role of markers in supporting the 
diagnosis of AD at the very early clinical stages, i.e. when the patient is symptomatic but does not 
fulfill the criteria for dementia (respectively, prodromal AD, or MCI due to AD). Within this 
perspective, neuropsychological tests can be considered as a “gateway biomarker” in the AD 
diagnostic process (Cerami et al., 2017). In the case of typical presentations of AD, the performance 
in episodic memory tests is crucial for early diagnosis, and is the basis for the definition of MCI or 
prodromal AD according to current diagnostic criteria. There is however no consensus on the most 
appropriate tests to be employed. Episodic memory tests are sensitive, but not specific. In addition, 
they are unsuitable to measure disease severity and progression as they reach floor levels early in 
the disease course. Tests controlling for effective memory encoding and retrieval may be 
particularly suitable to identify the hippocampal amnestic syndrome, which is typical of AD with 
the presence of a paradigmatic and specific episodic memory involvement, characterized by a 
diminished free recall ability, which is only marginally improved by cueing. In this regard, the Free 
and Cued Selective Reminding Test (FCSRT) has been used with the aim of maximizing the 
differentiation between the genuine hippocampal deficit of AD and age-associated memory 
dysfunctions, due to impaired attention, inefficient information processing, and ineffective retrieval 
(Grober and Buschke, 1987).  The FCSRT, as well as the “bedside” 5-Word cued recall test (Dubois 
et al., 2002; Economou et al., 2016) increase the specificity for AD (Dierckx et al., 2009; Wagner et 
al., 2012). There is also evidence supporting the value of the FCSRT to predict progression towards 
dementia in at risk populations (Sarazin et al., 2007).  
An important issue is the role of neuropsychological testing in diagnosis atypical AD presentations. 
The three main forms defined by the IGW-2 criteria (Dubois et al., 2014), i.e. the language, 
visuospatial and behavioral presentations, require specialized neuropsychological assessment for an 
adequate diagnostic evaluation, in particular in the early stages, for follow-up and for evaluation of 
treatment effects. The logopenic/phonological variant of primary progressive aphasia (PPA) is by 
far the most common language presentation of AD (Spinelli et al., 2017).  Only very few tools have 
been specifically developed for the assessment of language deficits in PPA patients, and for the 
characterization of the PPA subtype, which is relevant for a probabilistic diagnosis of the 
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underlying pathology. The language tests in common use (e.g. Aachener Aphasie Test (AAT), 
Huber et al., 1980) and the Boston diagnostic aphasia examination (BDAE) (Kaplan, 1983) have 
not been specifically developed for the differentiation of the subtypes of PPA,  but rather for the 
evaluation of aphasia due to stroke.  A “minimal” procedure, allowing a classification according to 
the current diagnostic criteria (Gorno-Tempini et al., 2011) must include: 
a. a qualitative and quantitative observation of patient’s speech and language during a semi-
structured interview, which can be based on a complex picture description. The main parameters to 
be assessed are: lexical production rate and phonological/articulatory errors; disorders of fluency 
(pauses and repetitions); lexical typology; and syntactic structure and complexity. On this basis, it is 
possible to conclude for the presence or absence of motor speech disorders and agrammatism, 
necessary for the differential diagnosis with other PPA variants, seldom associated to AD 
pathology; 
b. tasks of picture naming and  word-picture matching to assess single word comprehension; 
c. a repetition test allowing an assessment of phonological and auditory verbal short-term 
memory abilities, typically impaired in logopenic aphasia ; 
d. sentence-picture matching tasks to assess syntactic comprehension.  
The visuo-spatial presentation of AD is posterior cortical atrophy (PCA) (Crutch et al., 2017). This 
clinical picture is characterized at the onset by prominent visuo-spatial cognitive features, such as 
deficits in space and object perception, simultanagnosia, constructional dyspraxia, prosopoagnosia, 
oculomotor apraxia, optic ataxia and alexia. As in the case of logopenic aphasia, all these aspects 
can be quantified using a wide array of tests, which have been developed for the 
neuropsychological evaluation of focal brain damage, such as the copy of Rey’s figure (Rey, 1941). 
An excellent screening battery, which allows to evaluate in a short amount of time the function of 
both ventral and dorsal visual processing pathways is the Visual Object and Space Perception 
Battery (Warrington and James, 1991). 
Finally, a true challenge for neuropsychological assessment is the third variant of atypical AD 
presentation, characterized by “frontal” features (Ossenkoppele et al., 2015). The crucial issue here 
is the differential diagnosis with the behavioral variant of frontotemporal dementia, which requires, 
in addition to biomarker evidences, a detailed neuropsychological assessment. This must not be 
limited to classical “frontal lobe tests”, such as the Wisconsin Card Sorting (Heaton et al., 1993) or 
the Stroop test (Stroop, 1935), but requires a  comprehensive evaluation of behavioral disorders and 
neuropsychiatric disturbances (for example, with the Frontal Behavioral Inventory, Kertesz et al., 
1997, and the Neuropsychiatric Inventory, Cummings et al., 1994), as well as an assessment of 
social cognition performance (see, for example Torralva et al., 2009). 
To summarize, a clear definition of the cognitive/behavioral phenotype is the first step towards a 
biomarker-supported pathological diagnosis of AD. The identification of the very early/prodromal 
stages of both typical (hippocampal episodic memory) and atypical (visuo-spatial abilities, 
language, executive function and behavior) presentations is one of the main goals of 
neuropsychological assessment. There is clearly a need for harmonization of tools and procedures 
and for the collection of high quality psychometric data. This priority, however, should not obscure 
the importance to develop innovative ideas based on the advances in cognitive neuroscience 
research. The recent focus on pre-clinical rather than prodromal stages (Dubois et al., 2016) offers a 
great opportunity for the development of novel, continuous measures assessing cognitive efficiency 
and functional status. Taking advantage of the technological possibilities, such as those offered by 
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smartphones and social media (Wilmer et al., 2017), is one of the many interesting developments to 
be explored in the next few years.   
 
4.3 Neuroimaging markers  
Advances in neuroimaging techniques, including magnetic resonance imaging (MRI) and Positron 
Emission Tomography (PET), have strongly contributed not only in increasing our understanding of 
clinical and pathophysiological aspects of dementias, but also in improving the diagnostic 
confidence in clinical settings (McGinnis, 2012). MRI, thanks to its ability to image in vivo soft 
tissues non-invasively and with detailed anatomical resolution, shows high sensitivity in detecting 
the presence and extension of macroscopic abnormalities of the brain tissue (Bozzali et al., 2016)  
and in excluding alternative diagnoses that may mimic a neurodegenerative form of cognitive 
decline such as brain tumors, normal pressure hydrocephalus, subdural hematoma, and 
cerebrovascular encephalopathy. On the other hand, PET imaging has proven high sensitivity in 
detecting metabolic abnormalities at individual level since the early clinical stages of cognitive 
decline (Iaccarino et al., 2017). Additionally, novel tracers, including beta-amyloid and tau-protein 
ligands have become available with the potential of detecting in vivo specific pathological features 
of brain tissue degeneration (Jack et al., 2017).  
Conventional MRI. Besides the exclusion of secondary causes of dementia, conventional MRI may 
be used to address a correct diagnosis of AD only in a proportion of cases, mainly based on 
assessment of regional brain atrophy. The simplest way to determine regional changes of brain 
volumes is to use rating scales based on visual examination of T1-weighted MR images (Scheltens 
et al., 1992; Wahlund et al., 2001), such as the “medial temporal lobe atrophy” MTA scale 
(Scheltens et al., 1992). The use of MTA has shown high accuracy in determining the severity of 
local atrophy in cross-sectional studies that compared AD patients against healthy controls (Ridha 
et al., 2007). Conversely, MTA appears to be poorly informative in detecting longitudinal 
volumetric changes over time (Ridha et al., 2007; Persson et al., 2017). There have been introduced 
specific visual rating scales also to quantify the presence and severity of macroscopic white matter 
(WM) abnormalities. The Age Related White Matter Changes (ARWMC) (Wahlund et al., 2001) 
and the Fazekas’ scales (Fazekas et al., 1987) allow a simple assessment of macroscopic WM 
lesions. In the diagnostic suspect of AD, taking altogether the information given by MTA and WM 
lesion assessment, three different patterns may schematically be identified: 1) severe MTA and 
minimal WM abnormalities; 2) minimal MTA and severe WM abnormalities; 3) moderate MTA 
and moderate/severe WM abnormalities. In the first two cases, conventional MRI strongly 
contributes in increasing the diagnostic confidence of neurodegeneration. Although the contribution 
of conventional MRI remains limited in the third case, however a strict association has been 
recently shown between brain amyloid deposition and both presence and severity of periventricular 
WM lesions (Marnane et al., 2016).  
Quantitative Brain Volumetrics. The development of sophisticated registration algorithms has made 
it possible to bring volumetric images from different subjects into a common space and to identify 
differences between groups (e.g., patients vs. controls) or correlations with clinical/psychometric 
measures, on a voxel-by-voxel level basis. For data-driven analyses, voxel-based morphometry 
(VBM) is one of the most popular techniques to investigate dementias (Ashburner and Friston, 
2000). This approach is operator-independent and does not require any a priori hypothesis on the 
anatomical localization of the brain tissue loss  (i.e., voxel-wise analysis) (Bozzali et al., 2006). 
13	
	
Different statistical designs can be employed, which allow between-group comparisons to be 
performed as well as correlations between distributions of regional GM volumes and clinical, 
neuropsychological and behavioral variables. When applied to AD patients at different clinical 
stages, VBM has demonstrated a widespread pattern of GM atrophy, including not only the medial 
temporal lobe structures but also several other areas of the association cortex (Serra et al., 2010a, 
2014). Moreover, in patients with AD and aMCI it has been shown a strict association between 
cognitive profiles and regional patterns of GM atrophy (Serra et al., 2010a,b, 2014). Within the 
early stages of cognitive decline, MCI can also be dominated by neuropsychological deficits other 
than memory (i.e., non-amnestic MCI). Again, VBM has shown the ability to detect patterns of 
regional GM loss that fit with the non-amnestic neuropsychological profile, thus allowing a 
differentiation of MCI patients who are more likely to convert to other forms of dementias (Serra et 
al., 2013). Moreover, VBM has identified different patterns of GM volumes in association with 
different levels of cognitive reserve in patients with AD at different clinical stages (Serra et al., 
2011).  
Diffusion imaging. Diffusion imaging provides, through the measurement of diffusional motion of 
water molecules into brain cells, unique information to investigate the WM microarchitecture, 
connectivity and integrity (Basser and Jones, 2002; for a review on ‘connectivity’ see Rossini et al., 
2019, in press). Diffusion imaging has been widely used in studies investigating MCI and AD 
patients (for a review, see Bozzali et al., 2016). Some of them have reported a widespread alteration 
of WM tissue integrity in patients with AD at different clinical stages and using both a whole brain 
analysis (Serra et al., 2010a; Liu et al., 2011) or focusing on specific WM tracts (Serra et al., 2012; 
Bozzali et al., 2012). For instance, a study based on diffusion tractography of the cingulum (i.e., the 
main pathway of connection between the limbic system and the rest of the brain) has shown a 
progressive disruption of this structure over the transitional stage from MCI to AD (Bozzali et al., 
2012). Interestingly, this WM damage accounts, in combination with regional GM loss, for the 
cognitive features of preclinical and clinical stages of AD (Bozzali et al., 2012). A novel method of 
diffusion imaging analysis, called anatomical connectivity mapping (ACM), has been proposed to 
assess changes in structural brain connectivity across the whole brain (Bozzali et al., 2011,2013).  
Functional MRI. Neuronal activity can be investigated non-invasively, but indirectly, through blood 
oxygenation level dependent (BOLD) functional MRI (fMRI). fMRI can be used to assess changes 
of brain activation in response to performance at cognitive tasks e.g., memory, visuo-spatial 
abilities, executive functions, emotion processing, etc). On the other hand, fMRI can be used at rest 
to record coherent fluctuations of brain activity over time, in the so-called resting-state fMRI 
technique. In this case, fMRI provides information on functional brain connectivity within specific 
networks, some of which have been associated with specific cognitive functions. fMRI 
investigations based on active tasks of episodic memory have reported, in AD, reductions of 
functional activity in the hippocampus and other temporal lobe areas, and increased activity in the 
parietal association cortex (Peters et al., 2009). Conversely, other studies have reported patterns of 
decreased functional activity (during memory tasks) not only in the temporal lobe but also in 
parietal and frontal regions (Golby et al., 2005). Studies involving patients with MCI have generally 
reported increased activation in brain areas related to the administered tasks (for a review, see 
Pihlajamäki et al., 2009). There is some evidence that the increase of functional activity might 




Among various functional networks, the default-mode network (DMN) (Greicius et al., 2003) has 
been intensively investigated in patients with AD. This network includes the posterior cingulate 
cortex, the inferior parietal and the medial prefrontal cortex, and these regions are believed to be 
similarly modulated by cognitive tasks. A study involving patients with AD, patients with aMCI 
and healthy controls, has i shown that functional disconnection may precede the GM atrophy in the 
posterior cingulate cortex, supporting the hypothesis that atrophy (at least in some regions of AD 
brains) is likely to reflect a long-term effect of brain disconnection (Gili et al., 2011). In addition, 
DMN connectivity has been found to be modulated by individual levels of cognitive reserve 
(Bozzali et al., 2015), thus helping clarify the neurobiological substrate of compensation 
mechanisms that delay the clinical impact of AD pathology.  Recently, a modulation of connectivity 
due to cognitive reserve was observed also at larger scale in the brain, based on more sophisticated 
brain connectomics. MCI patients with higher cognitive reserve showed increased functional 
connectivity in a large network of fronto-parietal nodes and decreased connectivity in a network 
involving fronto-temporo-cerebellar nodes (Serra et al., 2017). Interestingly, this effect was clearly 
detectable in MCI patients only, suggesting that the cognitive reserve acts to counterbalance AD 
symptoms in a specific time window of the transitional stage between normal aging and dementia.  
Metabolic Imaging. PET imaging is in principle capable of detecting disease processes when there 
is no evidence of structural changes on MRI (Phelps, 2000). 18Fluorodeoxyglucose (18FDG-PET) is 
a widely available PET tracer that reflects the local glucose metabolism as a proxy index for 
neuronal activity (Bohnen et al., 2012). Typical 18FDG-PET finding in patients with AD is a pattern 
of reduced glucose uptake in temporo-parietal association areas, in the precuneus and in the 
posterior cingulate cortex (Iaccarino et al., 2017; Bohnen et al., 2012; Kato et al., 2016). 18FDG-
PET has demonstrated a high specificity in discriminating between patients with AD and healthy 
subjects (ranging from 70 to 90%), and between patients with AD and those with other forms of 
degenerative dementia (specificity of 87%) (Knopman, 2012). Available evidence supports the 
position that an abnormal processing of β-amyloid (Aβ) peptides is the initiating event of AD 
pathophysiology, which eventually leads to accumulation of Aβ plaques in the brain tissue (Hardy 
and Selkoe, 2002). This process occurs when individuals are still cognitively intact, many years 
before the occurrence of clinical manifestations of AD. Amyloid PET imaging has been proposed as 
a tool for early detection of AD pathology in vivo (Rowe and Villemagne, 2013). In AD, amyloid 
PET imaging has shown increased tracer binding in areas known to have high concentrations of 
amyloid plaques such as the medial and orbitofrontal regions, the lateral parietal and temporal 
cortex, the precuneus and posterior cingulate (Rowe and Villemagne, 2013). Nevertheless, β-
amyloid deposition is widely present also in normally functioning brains, and disentangling the 
aging effect from AD pathology remains an issue, especially in cases of late-onset AD. When 
considering the prognostic value of PET imaging on the risk of conversion to AD, measures of 
brain glucose metabolism and amyloid load are both extremely powerful markers. In a longitudinal 
study, 18FDG-PET positivity performed as the best individual predictor for AD conversion, but the 
combination of both, 18FDG-PET and 11C-PiB-PET imaging, improved classification accuracy 
(Iaccarino et al., 2017).  Finally, although future studies are needed to clarify their specific role, 
PET imaging shows nowadays the potential of detecting in vivo specific aspects of 
neurodegeneration, including not only beta amyloid deposition, but also tau protein accumulation 





4.4 Fluid markers  
 
In the last two decades, several fluid markers for specific pathologic changes and non-specific 
markers of oxidative damage or inflammation in AD patients have been proposed and tested. Over 
time, the most consistent findings have been obtained with three CSF markers: the Aß1-42 peptide 
(Aß42), the total tau protein (T-tau) and the phosphorylated tau protein (P-tau) (Blennow et al., 
2006, 2010). Although protein content is lower in cerebrospinal fluid (CSF) than in serum, CSF 
markers are preferred over blood/plasma biochemical markers in AD to reflect brain 
pathophysiology, because the brain is in direct contact with the CSF by unrestricted bi-directional 
flow of proteins and the CSF is withdrawn from direct impact of the peripheral system through the 
restricted transportation of molecules and proteins by the blood–CSF barrier (Olsson et al., 2016). 
Indeed, the three CSF markers are related to the three main pathological changes that occur in the 
AD brain: amyloid-ß (Aß) deposition into extracellular Aß plaques, intracellular neurofibrillary 
tangles (NFT) formation, and neuronal loss. Particularly, in AD patients, Aβ42 is found at low 
concentrations due to cortical amyloid deposition, T-tau at high concentration due to cortical 
neuronal loss, and (P-tau) at high concentrations, reflecting cortical tangle formation: this pattern is 
commonly referred to as the “AD signature” (Galasko et al., 1998; Clark et al., 2003; de Leon et al., 
2006; Fagan et al., 2007, 2011; Shaw et al., 2009).  
There are numerous reviews on the diagnostic performance of the CSF markers, including in the 
early stages of AD (for a recent review see Olsson et al., 2016). In particular, combining these CSF 
markers adds to diagnostic accuracy, both for early identification of AD and to differentiate AD 
from non-AD dementias with sensitivity and specificity reaching 85–90% (Blennow et al., 2010). 
The CSF markers are also highly predictive of progression to AD from MCI (Hansson et al., 2006; 
Fagan et al., 2007; Li et al., 2007; Diniz et al., 2008; Brys et al., 2009; Mattsson et al., 2009; Snider 
et al., 2009; Shaw et al., 2009). Subsequently, the diagnostic criteria for AD dementia established 
by the NIA-AA (McKhann et al., 2011) and the research criteria by the IWG-2 (Dubois et al., 2014) 
recommend the use of fluid markers (reduced levels of Aβ42 and elevated levels of T-tau and P-tau 
in CSF), when there is a need to increase the certainty that the underlying cause of a dementia 
syndrome is AD. Similar recommendations for markers were presented in the most recent European 
Federation of Neurological Societies guidelines for the diagnosis and management of AD (Hort et 
al., 2010) and other dementias (Sorbi et al., 2012). In the diagnostic criteria for MCI because of AD, 
developed by NIA-AA, a positive Aß marker (either by amyloid-PET or CSF) together with the 
presence of a neuronal injury marker, such as medial temporal lobe atrophy or elevated levels of T-
tau and P-tau in the CSF, indicates that the MCI syndrome may be because of AD, whereas 
negative Aß markers suggest that MCI is unlikely because of AD (Albert et al., 2011). The IWG-2 
criteria for prodromal AD are the presence of episodic memory decline of the hippocampal type as 
the leading clinical symptom and positive marker evidence from either CSF or imaging that 
supports the presence of underlying AD pathology (Dubois et al., 2014).   
Although such bulk of evidences, further research, validation, and standardization are required for a 
clinical routine use (for recent recommendations about the use of CSF markers in clinical practice 
see Herukka et al., 2017, and Simonsen et al., 2017). At this regard, worldwide standardization 
efforts and quality control programs, including standard operating methods for both preanalytical 
(e.g., lumbar puncture and sample handling) and analytical (e.g., preparation of calibration curve) 
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procedures, together with efforts of biotechnology companies to develop highly reproducible assays 
on fully automated instruments are ongoing: these global standardization and harmonization 
measures will provide the basis for the generalized international application of CSF markers for 
both clinical trials and routine clinical diagnosis of AD (Blennow et al., 2014). 
 
 
5. EEG markers   
The human brain has about one hundred billion neurons, each establishing several thousand 
synaptic connections in an intricate matrix. This gigantic anatomo-functional scaffold can be 
modeled by myriads of network structures at micro-meso-macro-scale levels, with nodes and links 
that—at the macroscale level—dynamically cooperate with time-varying aggregations via transient 
and rapid locking/unlocking of the orchestrated firing synchronization of spatially separated 
neuronal assemblies (Singer, 1990; Jung et al., 2001; Makeig et al., 2002; Fuentemilla et al., 2006). 
Networks continuously re-shape throughout life via plastic mechanisms mainly utilizing the Long 
Term Potentiation/Depression (LTP/LTD) of synaptic transmissions. These depend upon the flow 
and type of input from internal and external environments as well as learning/training and aging 
processes. Network configuration and excitability also fluctuate in millisecond time frames, 
according to the cyclic changes of the cortical state (“cortical uncertainty,” Adrian & Moruzzi, 
1939), with an impact on their instantaneous efficacy for a given task’s performance. Such 
phenomena are reflected in the overall electromagnetic brain signals oscillating at various rhythms, 
which are recordable from the scalp via electroencephalography (EEG) and 
magnetoencephalography (MEG). Phase synchronisation (or coherence), phase-locking, 
entrainment, cross-frequency (or power synchrony), and phase reset of EEG rhythms measure the 
degrees of functional and effective connectivity between different brain areas and play a key role in 
the fluctuating cortical state, reflecting communication across spatially separate functional regions 
operating at different frequencies and cross-frequency synchronies (Buzsaki, 2005; D’Amelio and 
Rossini, 2012). EEG and MEG record time-varying changes of electromagnetic signals with a time 
resolution of milliseconds. They also follow the dynamics and hierarchies of neuronal assembly 
connection/dysconnection in analogy to the previously described binding/unbinding phenomena of 
neuronal firing phase coherence in animal microelectrodic recordings; these synchronization 
mechanisms are also linked with performance in cognitive functions (Uhlhaas and Singer, 2006; 
Buzsaki and Schomburg, 2015).  
Scalp resting state EEG rhythms reflect the summation of oscillatory membrane post-synaptic 
potentials generated from cortical pyramidal neurons, which play the role of EEG sources. Based on 
biophysical considerations, these sources were estimated as extended several squared centimeters 
(Nunez and Srinivasan, 2006; Srinivasan et al., 2007). These potentials can be considered as the 
oscillatory output of the resting state cortical system, while inputs were afferents coming from other 
cortical neural biomasses and thalamo-cortical neurons and neurons belonging to ascending 
reticular systems (Nunez and Srinivasan, 2006).  
Stationarity of resting state cerebral system (as opposed to nonstationarity) means that statistical 
features of scalp EEG rhythms are constant during recordings. Stationary condition can be observed 
for relatively short periods usually not longer than tens of seconds (Blanco et al., 1995) during 
which EEG rhythms can be examined by classical linear frequency analysis (Kaplan et al., 2005; 
Nunez, 2000).  
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In Clinical Neurophysiology, frequency analysis of scalp EEG rhythms reveals most spectral 
content under 50 Hz in standard physiological conditions as scalp and skull do act as spatial and 
frequency filters. Indeed, EEG rhythms can be investigated at higher frequency bands, e.g. 100-250 
Hz, using intracranial or MEG recordings that eliminate the skull filtering effects. In an ideal 
spectral analysis of scalp rsEEG rhythms, frequency bands of interest should be related to peaks in 
power density spectrum to denote relevant neural process (Lopes da Silva, 2013). EEG frequency 
analysis can be performed by many different procedures. We can arbitrarily distinguish two classes 
of EEG markers such as “synchronization” and “connectivity” (Babiloni et al., 2016a).  
Linearity and non-linearity is the behavior of a neural circuit, in which the output signal strength 
varies in direct or non-direct proportion to the input signal strength respectively. Herein we used the 
term “synchronization” to denote nonlinear oscillatory components of the brain system as a 
reflection of a collective oscillatory behavior of cortical neural populations generating EEG 
rhythms (Boccaletti et al., 2002). To produce scalp EEG rhythms, this “synchronization” 
mechanism must occur at a macroscopic spatial scale of some centimeters. Synchronizing neural 
populations in the cerebral cortex are the main source of scalp EEG rhythms in both resting state 
and task-related conditions.  
Typical linear characteristics of scalp EEG rhythms are power density/amplitude and phase. 
Magnitude and topography of power spectral density computed from scalp EEG rhythms is the 
most used marker of cortical neural synchronization for clinical and research aims. It is often 
computed by Fast Fourier Transform (FFT) from EEG epochs free from artifacts. Alternative 
advantageous procedures use parametric autoregressive models and wavelets analysis (Blinowska 
and Zygierewicz, 2012).  
Spectral analysis of EEG rhythms is typically done at fixed frequency bands. There is a promising 
convergence of spectral analysis results of EEG rhythms in patients with AD. Compared to seniors 
with intact cognition (Nold), these patients show widespread increase in δ and θδ power density; 
posterior decrease in α and β power density with frequency lowering of α power density peak 
(Adler et al., 2003; Jelic et al., 2000; Nishida et al., 2011; Scheeringa et al., 2012; van der Hiele et 
al., 2007). Nonlinear measures of “synchronization” markers pointed to a complexity loss of 
cerebral dynamics in AD in the same frequency bands (Besthorn et al., 1995; Jelles et al., 1999; 
Pritchard et al., 1994; Stam et al., 1995, 1996; Woyshville et al., 1994; Dauwels et al., 2010a; 
Azami et al., 2017a for a review). 
Scalp topography of EEG rhythms reflects the summation of EEG activity generated by frontal, 
parietal, occipital, and temporal source activities with poor spatial resolution of several centimeters. 
Compared to scalp EEG mapping, EEG source estimation presents the advantage that the cortical 
generators of EEG activity may be approximately disentangled. Of note, EEG source estimates are 
approximations of intracerebral neural current flows.  
Both nonlinear and linear mathematics can estimate neural current density of EEG cortical sources 
(Valdés-Sosa et al., 2009; Gramfort et al., 2013). These procedures model 3D tomographic patterns 
of EEG cortical generators into a spherical or an MRI-based head model representing electrical 
properties of cerebral cortex, skull, and scalp, typically co-registered to Talairach brain atlas 
(Talairach and Tournoux, 1988; Yao & He, 2001; Pasqual Marqui 2002, 2007a,b ). Source 
localization procedures estimate the current intensity of all dipoles (e.g. hundreds to thousands) of 
cortical model to explain scalp EEG amplitude/power density. These solutions are mathematically 
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regularized to account the fact that the EEG inverse problem is under-determined and ill-
conditioned.  
 
Practically speaking, EEG data analysis may be divided into a two-step process: first, the signals 
recorded from all sensors are ‘de-noised’, that is, sensor noise and electromagnetic signals 
generated by unwanted sources are eliminated to the greatest possible extent; second, the current 
density distribution or parameters of interest are estimated from the cleaned sensor recorded signals. 
This phase, sometimes called preprocessing, is devoted to the extraction of the source under study 
from the whole population of electromagnetic sources, including also the artefactual ones. The first 
step aims at improving signal-to-noise ratio by excluding portions of highly noisy data. This step 
includes two tasks, almost independent of the particular source under study, thus the digital signal 
processor (DSP) before writing the data to the disk may just accomplish them: electromagnetic 
signals are examined in order to exclude the portion of the data corrupted by: 1)  analog to digital 
(ADC) overflows or by noise or possible instrument failures; 2) subject head movements or eye 
movements. 
The next step maximizes the signal-to-noise ratio by trying to separate, as much as possible, the 
signal from the noise using information on the specific source under study. In some cases, it is 
possible to observe neural activity synchronization by supplying to the subject an external stimulus, 
or instructing the subject to perform a specific task. Asking to repeat this task many times and 
triggering the onset of analysis on the task onset, an average may be obtained over all the epochs. In 
this way, only the electromagnetic field originated by a source time-and-space correlated with the 
task is left unchanged, while all other signals are reduced by a factor 1/√N, where N is the number 
of averages.  
Given the high relevance of analyzing resting state activity, alternative procedures to enhance the 
signal to noise ratio were developed including Blind Source Separation (BSS) methods such as 
Independent Component Analysis - ICA (Hyvarinen et al., 2001) and semi-BSS such as Functional 
Source Separation – FSS (see Fig. 2) (Tecchio et al., 2007; Porcaro and Tecchio, 2014). 
A relevant step relates the determination of the current density distribution inside the brain, 
especially in some region of interest. The diverse approaches to solve the so-called inverse-problem 
range from single and multiple dipoles (Scherg and Berg, 1991), to distributed sources, which 
include Multiple Signal Classification – MUSIC (Mosher et al., 1992), the recursively applied and 
projected-MUSIC, RAP-MUSIC (Mosher and Leahy, 1999), the minimum norm estimates, MNE 
(Hämäläinen and Ilmoniemi, 1994) and the Low resolution brain electromagnetic tomography – 
LORETA (Pascual-Marqui et al., 1994). Furthermore, spatial filtering procedures, like beam 
forming (for example synthetic aperture magnetometry – SAM (Vrba and Robinson, 2001), are also 
alternatives. 
Given the side effects in solving the inverse problem, which depends on biophysical properties 
external to EEG-MEG information and in part unknown (proper conductivity of diverse extra-
cerebral tissues), neuroscientific community spends huge efforts to extract the information of 
interest from the identified sources derived from BSS and semi-BSS methods.  
In both cases stronger analysis tools exploits graph theory (Miraglia et al., 2017), which returns 
indicators of the balance between the local connectedness and the global integration of a network 
mainly concentrating the evaluation on the connectivity features of the involved regions. 
Approaches concentrating on the dynamic features of the neuronal activity include the power 
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estimate in diverse oscillatory frequency ranges and non-linear measures assessing ether the 
complexity of the signal (Escudero et al., 2015) or its fractal dimension (Smits et al., 2016).  
 
6. The relevance of EEG in AD investigation 
6.1. Baseline EEG 
There is a vast literature on EEG abnormalities in pathological brain aging (for a review see Rossini 
et al., 2006). Compared to cognitively intact elderly (Nold) subjects, AD patients contain excessive 
δδ and a significant decrement of posterior α rhythms (Huang et al., 2000). Similarly, MCI display a 
significant decrease of α power compared to Nold (Koenig et al., 2005). Furthermore, a prominent 
decrease of EEG spectral coherence in the α band in AD has been reported (Jelic et al., 2000; Adler 
et al., 2003).  
The EEG θ power was found to be higher in aMCI who will convert to AD. In fact, a high 
predictive accuracy of baseline EEG features for predicting future decline was found (Prichep et al., 
2006). Furthermore, the analysis of EEG coherence (the phase different of the oscillations of a 
given frequency at two different electrodes) has been shown to contribute to the differentiation of 
AD from Nold (Adler et al., 2003) and to the prediction of aMCI conversion to AD (Jelic et al., 
2000). However, findings were usually significant only at a group level (de Haan et al., 2012a); 
moreover, relatively small samples were investigated with a briefer than required follow up. Despite 
such limitations, an important review (Dauwels et al., 2010a) has summarized the progresses in the 
diagnosis of AD: generalized slowing of the spectral profile, reduced complexity and perturbations 
in EEG.  
Similar features of EEG sources with some attenuation in amplitude as seen in AD patients were 
also observed in MCI subjects (see a review in Babiloni et al., 2016a; Canuet et al. 2012). δThese 
findings were confirmed by an independent approach based on minimum-norm depth-weighted 
estimation (Hsiao et al., 2013). Relative to aMCI subjects, AD patients pointed to reduced activity 
in precuneus, posterior cingulate, and parietal regions as well as increased activity in δ or θ δsources 
in inferior parietal, medial temporal, precuneus, and posterior cingulate (Hsiao et al., 2013).  
Cross-validation of EEG source solutions was successfully done with correlation study with 
patients’ clinical/cognitive status and other AD markers. In AD subjects, clinical symptoms were 
positively correlated with abnormalities in β, α, and δ δsource activities (Dierks et al., 1993; 
Babiloni et al., 2009). Global cognitive status as revealed by MMSE score correlated negatively 
with δ/θ δsource activity and positively with α source activity (Babiloni et al., 2011, 2013, 2015; 
Gianotti et al., 2007; Canuet et al., 2012).  
Occipital, temporal, and parietal α source activities were maximum in aMCI patients with greater 
hippocampal volume, while they were intermediate in those with smaller hippocampal volume, and 
minimum in AD patients (Babiloni et al., 2009). Also, widespread α source activity was positively 
related to the volume of cortical gray matter in aMCI and AD subjects, while a negative correlation 
was found with widespread activity in δδ sources (Babiloni et al., 2013). In these subjects, there 
was a positive correlation between occipital-parietal α source activity and corresponding gray 
matter volume (Babiloni et al., 2015). Moreover, it was shown a negative correlation between EEG 
α dipolarity (e.g., uniformity of alpha potential distribution) and p-tau or p-tau/Aβ in cerebrospinal 






6.2. Evoked-related potentials 
 
ERPs are brain potentials time-locked to a sensory, cognitive, or motor event (Blackwood and Muir, 
1990; Luck, 2014; Peterson et al., 1995). The ERP technique usually involves averaging brain 
responses over a large number of experimental trials to increase signal-to-noise ratio. The resulting 
waveforms are informative about the time course of sensory and cognitive processes with high 
temporal resolution and provide spatial information about the location of the generating structures. 
ERPs allow studying neural correlates of information processing including sensory-motor and 
perceptual processes as well as higher cognitive operations such as decision making (Howe et al., 
2014).  
Among the various ERPs waves, the P300 component has the longest history in clinical applications 
and it is the most extensively used potential to study dementia and aging. It is a relatively large (10–
20 µV), scalp-positive ERP component that peaks around 250ms to 500 ms elicited by auditory, 
visual, or somatosensory stimuli (Polich and Kok, 1995), and is most often investigated using the 
so-called “oddball” paradigm where a train of frequent and irrelevant (standard/non-target) stimuli 
is interspersed with random, infrequent and task-relevant (target) stimuli that have to be detected 
(Polich and Criado, 2006; see Rossini et al 2006 for a review). P300 amplitude has been linked with 
memory processes but is perhaps more sensitive to the amount of attentional resources engaged 
during the task (Wickens et al., 1983; Gonsalvez and Polich, 2002). P300 latency indexes stimulus 
classification speed (Kutas et al., 1977), reflects stimulus more than response processing (Duncan-
Johnson, 1981; McCarthy and Donchin, 1981), and is generally independent of behavioral response 
time (Verleger, 1997; Ilan and Polich, 1999). Hence, peak latency can be used as a motor-free 
measure of cognitive function and has been found to be negatively correlated with mental function 
in normal subjects: shorter latencies are associated with superior cognitive performance from 
neuropsychological tests of attention and immediate memory (e.g., Polich et al., 1983, 1990; Polich 
and Martin, 1992; Stelmack and Houlihan, 1994; Reinvang, 1999), while increased latency is found 
in normal aging and increases further in dementia (Polich et al., 1986; Fjell and Walhovd, 
2001;Polich, 1997).  
In general, several previous studies consistently reported a prolonged P300 latency in AD patients 
compared to age-matched healthy controls (Pedroso et al, 2012); in particular it was found to be 
sensitive to deterioration of language, memory, and executive functions (Lee et al., 2013). Although 
the majority of P300 studies in AD focused on its latency, changes in its amplitude have also been 
found (Parra et al., 2012; Hedges et al., 2016) with sensitivity and specificity above 80% (Juckel et 
al., 2008). Two recent meta-analyses reported strong evidence that P300 latency can reliably 
differentiate between groups of MCI patients and controls (Howe et al., 2014; Jiang et al., 2015). 
Moreover, Jiang et al. showed shorter P300 latency and larger amplitude in stable MCI patients 
compared to MCI prodromal to AD (Jiang et al., 2015).  
Concerning other types of ERPs evidence shows that early components are usually less affected in 
AD, while later potentials reflecting higher cognitive processes, such as the above mentioned P300 
component, could be more effective for detecting the progression of cognitive decline and attention 
deficits: in fact, a decreased P600 and N400 repetition effect and also a delayed N200 latency can 
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be detected consistently in the early stage of the disease therefore providing an useful marker to 
predict the conversion from MCI to AD (Horvath et al., 2018).   
Finally, it’s noteworthy to highlight that the sensitivity and the specificity of ERP measurements 
showed great variability in the literature; therefore their diagnostic validity is considerd relatively 
poor. However, recent studies using promising clinical ERP approaches presented prediction 
accuracies of MCI/ AD progression in the 85–95% range (Bennys et al., 2007; Olichney et al., 
2008; Chapman et al., 2011). It can be concluded that besides their theoretical interest, there is an 
urgent need to standardize ERP assessment procedures in order to obtain results that allow direct 
comparisons across different studies and laboratories.  
 
 
6.3. Attention and working memory-related EEG features  
EEG signals associated with selective attention and working memory may detect very early and 
subtle changes in cortical network function at baseline in cognitively intact elderly individuals, to 
identify initial phases of subsequent cognitive deterioration. In a recent  study reported, participants 
were evaluated with an extensive neuropsychological battery (Giannakopoulos et al. 2009): those 
with a CDR score of 0.5 but no dementia and a score more than 1.5 standard deviations below the 
age-appropriate mean in any of the previously mentioned tests were confirmed to have MCI. 
Eighteen months after the baseline evaluation, only control subjects underwent cognitive 
reassessment with the same neuropsychological battery. Participants were placed in the dCON 
group at follow-up if they had a performance of 0.5 standard deviation lower than that at inclusion 
for two or more neuropsychological tests. The final sample included 55 individuals in the sCON 
group, 42 in the dCON group, and 45 in the MCI group. Continuous EEG was recorded during a 
simple attentional and a 2-back working memory task (Deiber et al., 2009). The Laplacian-
transformed EEG signal was segmented into epochs of 5500 ms, starting 1500 ms before stimulus 
onset. ERPs were obtained by stimulus-locked averaging of the signal with a 200 ms pre-stimulus 
baseline correction. To detect and characterize the event-related EEG oscillations whose latency 
and frequency ranges are not known a priori, a time-frequency (TF) analysis based on a continuous 
wavelet transformation of the signal was applied (complex Morlet’s wavelets). Analysis was 
performed in the θ, α and β frequency bands. Inter-trial coherence (ITC) is a time-frequency domain 
measure of event-related phase locking across trials, also referred to as phase-locking factor. ITC 
values range from 0 to 1, with higher values indicating higher coherence of the phase of oscillations 
across trials.    ITC analysis was performed in the θ (4-7 Hz), α (8-13 Hz) and β (14-25 Hz) 
frequency bands (for review see Deiber et al., 2015).  
ERSP (Event-related spectral power) and ITC (inter-trial coherence) were separately analyzed 
within the θ, α and β frequency bands over the 9 most posterior electrode sites where their 
amplitude was maximal. In both tasks, stimulus presentation elicited a transient increase of θ power 
(ERS) followed by a decrease of α and β power (ERD).  An increased α and β ERD as well as 
decreased β ITC during the successful performance of simple attention and working memory tasks 
are associated with the subsequent development of neuropsychological deficits in healthy elderly 
controls. In the α range, the posterior ERD was enlarged in dCON and MCI as compared to sCON, 
suggesting an increased mobilization of resources engaged for attention and working memory in 
these groups. In the presence of preserved task performances, such increases were usually 
interpreted as compensatory phenomena related to the necessity to enhance the activation of the 
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memory networks in order to guarantee accurate task achievement. Alternatively, the increased 
activation could represent an early sign of loss in brain efficiency. Modulations in the β range were 
less obvious than in the α range. The beta ERD was of higher amplitude in dCON than sCON and 
MCI, but did not differ between sCON and MCI. This parameter (decrease of β activity) is 
determined by exogenous, bottom up factors (Engel and Fries, 2010). Consistent with this idea, the 
increase of β ERD in dCON as compared to sCON can reflect an enhancement of attentional 
recruitment devoted to stimulus processing.  
Inter-trial coherence is particularly sensitive to cognitive decline in the β frequency range during 
working memory activation, since this index was able to differentiate two cognitive levels within 
the control group, in contrast to θ and α phase-locking indices. Fine-tuning regulation within higher 
β frequency ranges, shown to relate to attentive behavior, would be affected in the very early phases 
of cognitive decline (Wrobel et al, 2007). 
 
6.4. Event-related synchronization/desynchronization (ERS-ERD)  
In the analysis of Event-related potentials, the early and late positive and negative potentials were 
studied in the time domain as the components named N100, N200, P200, P300, late positive 
potential, etc. Event-related potentials do not just have time-related changes, but these potentials 
also have frequency content properties. It is possible to analyze the frequency specific changes 
related to the function by different methodologies. The main aim in the analysis of frequency-
specific changes is to find out the increase or decrease of the power spectrum in a specific 
frequency band and also to find out phase information of this frequency band related to the given 
stimulation/task. Event-related increase in a specific frequency band is called Event-Related 
Synchronization (ERS) whereas event related decrease in a specific frequency is called Event-
Related Desynchronization (ERD). ERS/ERD analysis was first introduced by Pfurtscheller and 
Aranibar (1977) and by Pfurtscheller and Lopes da Silva (1999). Klimesch (1999) reported that 
event-related upper alpha desynchronization is positively correlated with long-term memory 
performance, whereas an increase of  ERS is positively correlated with the encoding of new 
information. Başar (1980) on the other hand mainly focused on the event-related increase of 
responses in a specific frequency band and called these responses as Event Related Oscillations. 
Furthermore, the role of pre-stimulus activity to post-stimulus responses both by analysis of power 
and phase information of the signal were shown (Başar, 1998, 1999) and the dynamics of event-
related oscillations and the evoked power spectrum, digital filters, phase locking factors and event-
related coherences for a specific function were explored in detail. Delorme and Makeig (2004) 
proposed their open toolbox to analyze the event-related desynchronization and synchronization and 
as well as inter-trial coherence, which is a measure of phase locking factor. During the analysis of 
time and frequency changes of event-related potentials, it is crucial to analyze all frequency bands 
with taking into consideration the change of event-related power spectrums and phase locking 
factors. In the last decade, researchers analyzed event-related time-frequency dynamics to find out 
the electrophysiological biomarkers for AD. Table 1 represents the event-related time-frequency 
dynamics of AD patients. 
Event-Related δ Responses: a decrease of digitally filtered δ responses is found in AD patients in 
comparison to healthy controls. Several researchers showed increased δ response correlated with 
the increased cognitive load (Güntekin and Başar, 2016). In AD the differentiation between “target” 
and “non-target” responses in δ response was not found as in controls, but there was a δ response 
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decrement during both visual and auditory oddball paradigms (Caravaglios et al., 2008; Yener et al., 
2008, 2012). Furthermore, the decrease of δ response was correlated with the decrease of frontal 
brain volume (Yener et al., 2016). MCI patients had also decreased δ responses during “oddball 
paradigm” (Kurt et al., 2014; Yener et al., 2013). Furthermore, there was a gradual decrease in δ 
responses being higher in healthy elderly controls and lower in MCI and the lowest in AD (Yener 
and Başar, 2013). 
Event-Related θ Responses: θ responses were mainly increased in frontal-central areas during 
cognitive paradigms. θ ERS is positively correlated with the encoding of new information 
(Klimesch, 1999), increased θ power and θ phase locking was observed during working memory 
paradigms (Klimesch et al., 1997; Başar et al., 2001; Sauseng et al., 2010). Alzheimer’s and MCI 
patients had abnormalities in θ response due to their cognitive decline (Cummins et al., 2008; 
Deiber et al., 2009, 2015). Deiber et al. (2009) showed that progressive MCI had reduced baseline 
induced θ power than stable MCI and healthy controls during N-back task. In a recent study Deiber 
et al. (2015) reported decreased θ ERS in MCI patients in comparison to healthy controls. 
Caravaglios et al. (2010) showed that AD patients had increased prestimulus θ activity and reduced 
event-related θ power in comparison to healthy controls during auditory oddball paradigm.  
Event-Related αResponses: α response has an important role in sensory, cognitive and memory 
processes (Klimesch, 1999). Although Klimesch’s inhibition theory had high acceptance in the 
research area, many studies are showing that increase of α response and/or α ERS has essential 
functional correlates, including sensory and memory functions (for a review see Başar, 2012; Başar 
and Güntekin, 2012). α ERD was reduced in healthy aging subjects (Gevins et al., 1997, 2000). 
Babiloni et al. (2000) during movement related task showed an abnormal preponderance during 
both movement related β ERD and post-movement β and α ERS values in AD. In a MEG study, 
Babiloni et al. (2005) reported delayed α ERD latency and increased α ERD peak in patients with 
dementia in comparison to healthy young and elderly subjects during the visual delayed choice 
reaction task. On the other hand, Karrasch et al. (2006) found reduced ERD in AD patients during 
auditory-verbal Sternberg memory task. In a recent study Fraga et al. (2017) also reported 
decreased α ERD in patients with MCI and AD in comparison to healthy controls during N-Back 
task.  To our knowledge there is only one study that analyses event-related phase locking α 
responses in MCI(Deiber et al., 2015) that showed decreased α phase locking in MCI patients in 
comparison the healthy controls. New researches with including large patient groups are needed for 
understanding the dynamics of α responses in AD patients.  
Event-Related βResponses: β responses were mainly related to sensory-motor functions, these 
responses are depressed during voluntary movement and motor imagery. However, the researches 
performed in the last decade have shown that β responses were also related to cognitive and 
working memory functions (Tallon-Baudry et al., 1998; Onton and Makeig, 2005; Ravizza et al., 
2005; Güntekin et al., 2013). Missonnier et al. (2007) found that β ERS was lower in progressive 
MCI and AD in comparisons to stable MCI and healthy controls during attentional detection task. 
Güntekin et al. (2013) showed that healthy controls had higher β phase locking and power during 
target stimulation in comparisons to “non-target” simulation, whereas this was not the case for MCI 
patients who had reduced β phase locking and power during auditory oddball paradigm.  Deiber et 
al. (2015) had also showed reduced ERS and β phase locking in MCI patients in comparisons to 
healthy controls during N-Back task.  
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Event-Related γ Responses: Evoked and induced γ responses play an important role both in sensory 
and cognitive processes. The increase of γ responses was reported during increased attention, 
memory processes, face and emotional picture recognition (Başar-Eroglu et al., 1996; Keil et al., 
1999; Singer, 1999; Tallon-Baudry and Bertrand, 1999; Herrmann et al., 2004; Jensen et al., 2007; 
Başar, 2013; Güntekin and Başar, 2014). Osipova et al. (2006) and Van Deursen et al. (2011) found 
increased γ responses in AD patients in comparison to healthy controls during auditory steady-state 
responses. Kuriomoto et al. (2012) analyzed the ERS/ERD in AD patients during Sternberg 
paradigm and reported that AD patients had reduced γ ERD. On the other hand, Başar et al. (2016) 
analyzed the filtered γ responses in three different sub frequency γ bands and four different time 
windows during visual oddball paradigm. These authors found that healthy controls had higher γ 
responses during 0-200 ms in comparison the AD patients, whereas AD patients had higher late γ 
responses. Both sensory and cognitive paradigm elicits early γ phase locking. Differentiation 
between sensory and cognitive paradigms was found in later time windows (200-400 ms and 400-
600 ms) (Başar et al., 2015). Therefore the γ responses should be analyzed in different time and 
frequency windows Analysis of ERD/ERS and phase locking of γ responses in AD patients during 
different sensory and cognitive paradigms are still needed to see the differentiation of γ responses in 
AD patients and healthy controls. Early and late γ responses should be analyzed separately to find 
out the differentiation of γ responses in AD patients comprehensively.  
 
6.5. Nonlinear EEG analysis  
The nonlinear behavior of the brain activity and its reflection in electrophysiological recordings 
such as the EEG has attracted substantial attention since the early 80’s (Jeong, 2004; Stam, 2005; 
Hornero et al., 2009). The reasons were twofold. Firstly, the emergence of methods based on Chaos 
Theory and their promise to achieve a deterministic characterization of complex time series 
(Grassberger and Procaccia, 1983; Wolf et al., 1985). Second, the fact that multiple neural 
processes are governed by nonlinear phenomena and such nonlinear dynamics are essential for 
healthy, adaptive cortical activity, up to the point that abnormal nonlinear dynamics has been 
related to a number of brain diseases (Breakspear, 2017). 
The early application of nonlinear methods based on Chaos Theory to spontaneous EEG activity in 
AD showed lower correlation dimension (D2) (Grassberger and Procaccia, 1983) and largest 
Lyapunov exponent (L1) (Wolf et al., 1985) values than control subjects (Jeong, 2004). These 
findings were interpreted as a reduction in number of variables needed to describe the dynamics of 
the EEG (D2) and a loss of flexibility in information processing (L1). This is because D2 is a 
measure of the geometry of the attractor that describes the EEG signals whereas L1 accounted for 
how much similar activity diverged over time (Jeong, 2004). Despite their different focus on static 
and dynamic properties of the EEGs, the results of both D2 and L1 were associated with a reduction 
of complexity in EEG activity due to AD (Jeong, 2004). Such interpretation of AD as a disease 
affecting the complexity of EEG signals is still valid today (Garn et al., 2015; Smits et al., 2016; 
Azami et al., 2017a). 
Nonetheless, the application of approaches based on Chaos Theory, such as D2 and L1, to EEG 
activity was quickly dismissed due to major methodological issues.  This led to a reexamination of 




(i) The characterization and modelling of non-linear dynamics in general, in contrast to only 
chaos. 
(ii) The development of novel nonlinear measures more suitable for application to noisy and 
multivariate recordings such as the EEG. 
Methods of nonlinear EEG analysis can be categorized into three main groups: 
• Fractal dimension metrics, including Katz and Higuchi’s definitions (Higuchi, 1988; Katz, 
1988). 
• Irregularity estimators, including sample entropy (Richman and Moorman, 2000) and 
permutation entropy (Bandt and Pompe, 2002). 
• Multiscale metrics (Humeau-Heurtier, 2015), including multiscale sample entropy (Costa et 
al., 2005) and derived approaches such as multiscale dispersion entropy (Azami et al., 
2017a). 
The concept of fractal dimension refers to a non-integer dimension of a geometric object. Hence, 
metrics such as Katz and Higuchi’s fractal dimension are conceptually related to D2. However, a 
crucial difference with D2 is that these fractal dimensions are computed in the time domain rather 
than requiring the reconstruction of the signal attractor, thus making them faster (Esteller et al., 
2011). These metrics have been applied to spontaneous EEG activity in AD showing that patients 
had reduced fractal dimension compared to healthy controls (Henderson et al., 2006), especially in 
temporal-occipital regions (Smits et al., 2016). 
A prolific and powerful framework for the nonlinear characterization of EEG activity is that of 
information theory and entropy measures. In this context, metrics such as sample entropy (SampEn) 
can be seen as conditional entropy estimators as measures of the rate of production of information 
within a signal (how much information previous samples of the time series provide about the future 
points) that indicate its level of predictability (Faes et al., 2015). Entropy metrics have been used to 
analyse spontaneous EEGs in AD and in MCI. The results showed reduced irregularity in AD 
patients’ EEG activity. Nonetheless, these results must be taken with caution due to the reduced size 
of the sample used in a number of those publications and the fact that the ability to distinguish 
between patients and controls may depend on the values of the parameters used in the nonlinear 
metrics (Simons et al., 2018). 
The third major category of nonlinear measures are those related to the multiscale behavior of 
signals and the concept of complexity, which is here understood as sophisticated behavior beyond 
that of both fully predictable and deterministic systems and that of merely random oscillations 
(Costa et al., 2005; Yang and Tsai, 2013). Thus, completely ordered (i.e., predictable) or random 
systems are not physiologically complex (Goldberger et al., 2002). A working measure of 
complexity was proposed by quantifying entropy (originally SampEn) over multiple temporal scales 
obtained from “coarse-grained” versions of the signals under analysis (Humeau-Heurtier, 2015; 
Azami and Escudero, 2018a, 2018b). This method was called multiscale (sample) entropy (MSE) 
(Costa et al., 2005) and it has inspired the application of entropy metrics in a multiscale way ( 
Humeau-Heurtier, 2015; Azami et al., 2017a). 
MSE has been applied to reveal significant differences at a range of temporal scales between the 
EEG activity of patients with AD and controls (Escudero et al., 2006; Yang et al., 2013; Coronel et 
al., 2017). The results indicate that the spontaneous EEG activity of AD patients is less complex 
than that of controls at short temporal scales (associated with higher frequencies) but this tendency 
reverses at longer temporal scales (related to lower frequencies) where the AD patients seem to 
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have higher complexity (Escudero et al., 2006; Yang et al., 2013). Similar results have been 
obtained with multiscale dispersion entropy (MDE) (Azami et al., 2017b). This finding poses 
intriguing questions about the dependency of the complexity of brain activity on the temporal scales 
and frequency range under analysis. These issues have begun to be investigated recently (Courtiol 
et al., 2016; Azami et al., 2017b) but further research is needed to obtain a comprehensive 
interpretation of the application of multiscale methods to EEG signals and their relationship with 
other brain activity such as connectivity (Stam, 2005). This could be complemented with the use of 
appropriate computational models of EEG activity that would allow the inspection of the 
dependencies between structural and functional connectivity, diverse nonlinear estimators and 
biophysical parameters (Escudero et al., 2015; Ibanez-Molina et al., 2018).  
Arguably, one of the limitations of the nonlinear methods surveyed so far is that they are applicable 
to single (univariate) signals only. Multivariate versions have become recently available (Ahmed 
and Mandic, 2011; Labate et al., 2013; Azami et al., 2017a; Azami and Escudero, 2017; Deng et al., 
2017) but their use to inspect EEG activity is still in its infancy.  
Finally, it is worth mentioning that most results come from spontaneous recordings but the recent 
availability of methods applicable to short time series enable the nonlinear analysis of EEG activity 
recorded during tasks (Morison et al., 2013; Garn et al., 2015; Timothy et al., 2017), something that 
could result in increased sensitivity and/or specificity to early AD. 
6.6. Graph Theory Application and brain connectivity methods 
Time series of cortical electric neuronal activity estimated with the eLORETA algorithm can be 
used for estimating cortical connectivity, based on the following informal definition: “Two places 
are functionally connected if their activity time series are similar” (Worsley et al., 2005). However, 
from a formal point of view, there are many different ways to define similarity between signals. 
The methods proposed is performed using the exact low resolution electromagnetic tomography 
eLORETA (Pascual-Marqui et al., 2011). The eLORETA algorithm is a linear inverse solution for 
EEG signals that has no localization error to point sources under ideal (noise-free) conditions 
(Pascual-Marqui, 2002). The connectivity values are obtained by Lagged Linear Coherence 
algorithm as a measure of functional physiological connectivity (Pascual-Marqui, 2007a, 2007b). 
Based on the scalp-recorded electric potential distribution, eLORETA is used to compute the 
cortical three-dimensional distribution of current density (source localization). The description of 
the method together with the proof of its exact zero-error localization property are described in 
Pascual-Marqui 2007 and 2009 (Pascual-Marqui, 2007b, 2009).  
Several recent studies from independent groups (Canuet et al., 2011; Barry et al., 2014; Aoki et al., 
2015; Ikeda et al., 2015; Ramyead et al., 2015; Vecchio et al., 2014b, 2014c, 2015, 2016b) 
supported the idea of a correct source localization using eLORETA, even with the standard 20-
channel EEG montage (10-20 system).  
Via an individual analysis, brain connectivity can be computed by eLORETA software in the 
regions of interest (ROIs) defined according standardized Brodmann areas for left and right 
hemispheres (Talairach and Tournoux, 1988). Intracortical Lagged Linear Coherence, extracted by 
“all nearest voxels” or those in a sphere of 19 mm radius method, selected on the basis of the 
number of considered nodes (Pascual-Marqui 2007a, 2011), can be individually computed between 
all possible pairs of ROIs for each of EEG frequency bands (Kubicki et al., 1979; Niedermeyer and 
da Silva, 2005): δ, alpha 1, alpha 2, beta 1, beta 2, and gamma. Then, eLORETA current density 
time series of each Brodmann area is used to estimate the functional connectivity. The Lagged 
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Linear Coherence (LagR) algorithm has been implemented in eLORETA as a measure of functional 
physiological connectivity not affected by volume conduction and low spatial resolution (Pascual-
Marqui, 2007a).  
Network analysis requires that the original empirical data be represented in the form of a graph. 
This graph can be weighted or unweighted, and it can be directed or undirected. The first step is to 
decide what can be considered as a node, and what can be considered as a link (Stam, 2014). Core 
measures of graph theory can be computed with http://www.brain-connectivity-toolbox.net 
(Vecchio et al., 2014b; Miraglia et al., 2015, 2016) and represents the brain processes of 
segregation and integration. Segregation refers to the degree to which network elements form 
separate clusters and correspond to clustering coefficient (C) (Rubinov and Sporns  2010), while 
integration refers to the capacity of the network to become interconnected and exchange 
information (Sporns  2013), and it is defined by the characteristic path length (L) coefficient 
(Rubinov and Sporns  2010). 
The mean clustering coefficient is computed for all nodes of the graph and then averaged (Onnela et 
al., 2005; Rubinov and Sporns, 2010). It is a measure for the tendency of network elements to form 
local clusters (de Haan W et al., 2009). Starting by the definition of L (Onnela et al., 2005; Rubinov 
and Sporns, 2010), weighted characteristic path length Lw (Onnela et al., 2005; Rubinov and 
Sporns, 2010) represents the shortest weighted path length between two nodes. 
Small-worldness (SW) parameter is defined as the ratio between normalized C and L - Cw and Lw- 
with respect to the frequency bands. For example, to obtain individual normalized measures, in 
previous studies the values of the characteristic path length and of the clustering coefficient were 
divided by the mean obtained by the average values of each parameter in all EEG frequency bands 
of each subject (Vecchio et al., 2018,). Of note, it should be stressed that a normalization of the data 
with respect to surrogate networks could not be done due to the weighted values of the considered 
networks. Is the "graph theoretical" model superior to other types of EEG analysis in the AD 
diagnostic context? In order to answer this question the same type of classifier was compared to 
other kinds of methods of EEG analysis currently used for AD studies, applied to the same EEG 
epochs utilized for graph valuation, namely spectral coherence and power spectrum. The most 
significant result was obtained when analyzing the power density spectrum on all available subjects. 
The analysis showed 51.79% sensitivity, 100% specificity and 68.86% accuracy. These results are 
promising but less significant than the one from small world analysis (Vecchio et al 2018). 
Currently, network science is developing along a sophistication of network measures and models, 
introducing new concepts, such as cost-efficiency, hierarchical modularity, vulnerability to random 
or targeted attack, and the notion of rich clubs.  
Transitivity (Tw) is a simple measure of segregation based on the number of triangles in the 
network. It is computed as the fraction of the node's neighbors that are also neighbors of each other 
(Watts and Strogatz, 1998) and reflects, on average, the prevalence of clustered connectivity around 
individual nodes. Tw is a classical variant of Clustering Coefficient not affected by individual node 
normalization (Newman, 2003).  More sophisticated measures of segregation not only describe the 
presence of densely interconnected groups of regions, but also find the composition of these groups. 
This composition, known as the network's modular structure (community structure), represents the 
division of network into groups of nodes, with a maximally possible number of within-group links 
(within network connections are dense), and a minimally possible number of between-group links 
(between network connections are sparse). The degree to which the network may be subdivided into 
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such clearly delineated and non-overlapping groups is quantified by a single statistic, the 
Modularity (Qw). Unlike most other network measures, the optimal modular structure for a given 
network is typically estimated with optimization algorithms, rather than computed exactly.  Finally, 
Local efficiency (E!"#! ) is a measure of the efficiency of information transfer limited to neighboring 
nodes (i.e., nodes with direct edges to the node of interest), and indicates how interconnected 
neighboring nodes are to each other (Latora and Marchiori, 2001). 
The analysis of hierarchical organization of simultaneous oscillations of different frequencies and 
cross-frequency couplings during a given task performance has opened up opportunities for 
research into cognitive mechanisms (Buzsaki and Draghun, 2004).  Modulation in time of the 
connectivity pattern of the nodes in a task-related network accounts for much of the variability—i.e. 
from “excellent” to “poor” performance— of task output in apparently stable conditions of attention 
and mental concentration (Ferreri et al., 2014; Vecchio et al., 2014a, 2016b). In other words, the 
task-performance level and the task-related choice/behavior levels are largely written in the 
immediate architecture of the EEG networks’ connectivity, preceding (by a few seconds, usually) 
the task to be executed.  
Each EEG rhythm has a different physiological significance and a complete view—in time, space, 
and frequency domains—is needed to obtain a comprehensive analysis of the functional dynamics. 
It is worth mentioning that, depending upon the frequency content of the examined rhythm, the time 
discrimination of the activation within the network frame can be as short as few msec (down to 10 
msec in the high γ band). Because of this, EEG connectivity analysis facilitates an evaluation of the 
time hierarchy governing the serial/parallel activation of the nodes and their time/space relationship 
within a given network (i.e. whether A is active before, after, or in parallel to B).  
Aging processes modulate the network configuration of brain connectivity. Resting-state EEG 
characteristics are known to change across physiological aging, with gradual modifications in 
spectral power profile indicating a pronounced amplitude decrease of α (8–13 Hz) and a global 
“slowing” of the background EEG, with increases in power and changes in topographic location in 
the slower δ (2–4 Hz) and θ (4–8 Hz) frequency ranges (Dujardin et al., 1994, 1995; Klass and 
Brenner, 1995; Klimesch, 1999; Rossini et al., 2006). Aging processes affect posterior α rhythms, 
presumably because of the progressive degradation of the activity of dominant oscillatory thalamo-
cortical circuits in the resting awake adult brain (Steriade 1998; Brunia, 1999; Pfurtscheller and 
Lopez da Silva, 1999). They also affect the ability to synchronize in a network organization 
(Vecchio et al., 2017). 
 Dementias - particularly in the very early stages - mainly affect synaptic transmission and therefore 
represent “disconnection syndromes” (Dauwels et al., 2010b; Rossini et al., 2006; Babiloni et al., 
2011; Vecchio et al., 2015, 2017). However, a combined use of graph theory to explore brain 
connectivity from EEG signals and ApoE genotyping as a genetic risk factor for early interception 
of the “MCI prodromal to AD” condition have been attempted only very recently with highly 
encouraging results ( Vecchio et al, 2018). 
Many studies have looked at topographical changes of brain networks with different modalities and 
have examined structural and diffusion tensor imaging MRI, EEG/MEG and fMRI (see reviews by 
Xie and He, 2011; Tijms et al., 2013 Neurobiology of Aging). It is worth mentioning that fMRi and 
EEG connectivity do not reflect exactly the same phenomena; in fact; transient locking/unlocking of 
neuronal firing as reflected by phase synchronization does not require any energy consumption 
modification and does not produce any BOLD signal visible in fMRI.   
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Due to decreasing local and global connectivity parameters, the large-scale functional brain network 
organization in AD deviates from the optimal small-world architecture towards a more “ordered” 
type (as reflected by lower SW values), leading to a less efficient information exchange across brain 
areas in line with the disconnection hypothesis of Alzheimer’s Disease (D’Amelio and Rossini, 
2012).  
A statistically significant difference in the SW organization of those MCI subjects who will 
progress to AD (Converted= particularly those who can be defined rapid —i.e. 1-2 years— 
converters) was found; moreover, the Converted aMCI subjects do have SW characteristics very 
similar to those encountered in Alzheimer patients 1 to 2 years before their conversion (Time 0 of 
the study, Vecchio et al., 2018).  An abnormal increase in graph theory parameters in the 
Converted, with respect to the Stable MCI, has been observed for the low α rhythm, along with a 
decrease for the δ and γ rhythms. Such an effect should be interpreted in light of the physiological 
role the α rhythm. Αlpha frequencies constitute the leading characteristic of normal EEG activity at 
waking rest, which is usually defined as the “idling rhythms” of the adult brain (Niedermeyer and 
da Silva, 2005). Several studies support the hypothesis that α is a deterministic chaotic signal with 
several functional correlates –besides others (Stam et al 1999)- ranging from memory formation to 
sensory-motor processing  (Schurmann and Basar, 2001). In healthy individuals, α rhythm does 
work as an oscillatory component of brain activity and thus can be interpreted as a basic form of 
information transmission in the brain (Klimesch, 1999). Indeed, event-related activity studies have 
shown a positive correlation between α frequency and the speed of information processing, as well 
as a good cognitive performance (Klimesch, 1999). 
For the δ band, it is argued that, in the awake state, differently from α rhythms which are widely 
recordable and dominate in the posterior brain areas, δ rhythms are poorly represented, thus 
reflecting a condition of likely α-δ “reciprocal inhibition” (Rossini et al., 2006). Furthermore, it is 
well known that the anatomical or functional disconnection of lesioned cortical areas generates 
spontaneous slow oscillations in the δ range in virtually all recorded neurons. In particular, the SW 
decrease in the δ band represents a more structured behavior that could be interpreted as an increase 
of functional inhibition. The opposite holds true for the α band. 
A SW decrease in the γ band in the Converted MCI is in line with previous evidence (Vecchio et 
al., 2014c) showing a decrease of SW γ band in AD with respect to MCI and control subjects. The γ 
band (>30 Hz) mediates information transfer between cortical and hippocampal structures for 
memory processes (Vinck et al., 2013), particularly through feed-forward mechanisms (Abeles, 
1991) and coherent phase-coupling between oscillations recorded simultaneously from different 
neuronal structures (Fries, 2005). Both animal and human studies provide evidence that γ 
oscillations play a fundamental role in memory tasks.  Gamma neural activity is involved in 
numerous cognitive functions, including visual object processing, attention and memory (Tallon-
Baudry et al., 1998) and is also strongly associated with behavioral performance (accuracy and 
reaction time) in several memory tasks, including episodic memory, encoding and retrieval (Kaiser 
et al., 2008). Further, microelectrodic intraneural recordings demonstrated that γ oscillations are 
pivotal in spike phase synchronization, which is at the base of EEG connectivity mechanisms 
(Nikolic et al, 2013). 
In a population of 145 MCI subjects followed up for 2 years, the ROC curve showed for EEG SW 
characteristics with a >60% sensitivity (AUC 0.64, indicating moderate classification accuracy) for 
classifying the MCI state as a prodromal of AD when all subjects were used. These findings are in 
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line with previous studies (de Haan et al., 2012b; Vecchio et al., 2014c; Miraglia et al., 2016) in 
which SW characteristics were decreased in low frequency bands in patients with AD compared to 
MCI (Vecchio et al., 2018). That is, the MCI connectivity pattern was less random than that of the 
AD group. Moreover, significant differences between healthy elderly, MCI subjects and AD 
patients have been demonstrated by showing that physiological brain aging presents greater 
specialization (though lower values) of SW characteristics that are higher than normal in low EEG 
frequencies and lower in α bands (Vecchio et al., 2016a). Finally, the control analysis, with respect 
to AD patients, showed that Converted aMCI presented a graph theory pattern practically identical 
to the AD one. These findings suggest that EEG connectivity analysis, combined with 
neuropsychological evaluation in MCI, could be of great help in early MCI prodromal to AD 
identification as a first-line screening method and a means to intercept those subjects with a high 
risk for rapid progression to AD.  
It is of paramount interest to consider that the ROC curves showed that, when both phenotype and 
genotype characteristics (obtained at a low cost with widely available ApoE technology) are 
combined, the accuracy increased to 91.78 % (AUC 0.97, indicating a nearly optimal classification 
accuracy) for classifying the MCI state as a prodromal of AD (Vecchio et al 2018). This result is in 
line with the fact that the ε4 allele of the APOE gene is the major risk genetic factor for 
pathogenesis of late-onset Alzheimer disease (Huang and Mucke, 2012; Giri et al., 2016).  
The intrinsic characteristics of EEG rhythms contain relevant information on early 
neurodegenerative processes underlying AD. These processes begin long before clinical symptoms 
manifest, by deranging synaptic transmission and efficacy of brain dynamic connections (D’Amelio 
and Rossini, 2012). A plastic reorganization of the surviving neuronal circuitries -the neural 
“reserve”- contrasts such a neurodegenerative attack nulling or limiting the impact on daily living 
abilities. This is explaining the prolonged presymptomatic period (Rossini et al., 2006; D’Amelio 
and Rossini, 2012; Ferreri et al., 2003). In aMCI-C subjects, the SW characteristics provided 
reliable predictions of aMCI to AD progression within a relatively short timeframe. Moreover, rapid 
progression from aMCI to AD heralds an aggressive type of dementia with a rapid degradation of 
daily life skills. 
 
8. Toward automated EEG-based Alzheimer’s disease diagnosis? 
Alzheimer’s disease (AD) diagnostic accuracy rate by experienced clinicians varies from 80 to 90% 
and requires a huge amount of resources, from high-tech equipment to highly trained experts that 
are primarily found only at medical centers in developed countries (Sarazin et al., 2012). 
Consequently, non-invasive, low-cost and straightforward automated techniques for early AD 
diagnosis should be developed and improved. A promising candidate to achieve this goal is neural 
signal analysis through quantitative electroencephalography (qEEG). 
Notwithstanding, in order to develop a fully automated system to support clinicians in AD 
diagnosis, further improvements in qEEG algorithms are required regarding artifact removal 
techniques, feature extraction, feature selection and automatic classification strategies. The 
schematics of an ideal automated EEG-based system for early diagnosis of AD (leave-one-subject-
out training paradigm) is depicted in Fig. 3 (Cassani et al., 2014). Herein we will make a quick 
review on state-of-the art algorithms related to each of these system components. So far the great 
majority of studies in EEG-based biomarkers for AD early diagnosis rely on the resting-awake 
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experimental protocol, thus for the sake of compactness we will restrict our review to this approach 
As previously described, four main effects on EEG signals from Alzheimer's patients have been 
recurrently observed: slowing, reduced complexity, decreased synchrony, neuromodulatory deficit 
in EEG rhythms and loss of frequency-dependent connectivity. As for the former three effects, a 
comprehensively review was performed (Dauwels et al., 2010a). For connectivity analysis the 
Reader is referred to the related section of this manuscript. Regarding the quantification of the 
neuromodulatory activity, amplitude modulation analysis was propositioned as a spectral-temporal 
technique, allowing direct characterization of cross-frequency interaction effects by measuring the 
rates at which EEG bands are modulated (Falk et al., 2012; Fraga et al., 2013). The procedure of 
feature averaging is an interesting additional tool proven to improve the accuracy in AD diagnosis 
(Fraga et al., 2013). This step is similar to the epoch averaging commonly performed in event-
related potential studies, but differs in the sense that it runs in the (non-linear) feature domain rather 
than in the time domain. 
The combination of all the above-mentioned feature extraction techniques results in a wide-ranging 
collection of features. For this reason, a feature selection process necessarily should be done in an 
automated or at least in a semi-automated way. A large number of machine learning algorithms can 
be used to accomplish this task. A widely used procedure for both feature selection and 
classification in diagnosing AD applications is support vector machine (SVM), which achieved up 
to 98% accuracy in early AD detection (Falk et al., 2012; Fraga et al., 2013; Trambaiolli et al., 
2011). One of the major advantages of SVM is that, using it together with the L1-norm as 
penalization, it leads to sparse weight vectors and allows feature selection and classification to be 
accomplished in the same step (Cassani et al., 2017). An interesting variation of SVM is the 
Relevance Vector Machine (RVM), which replaces the binary SVM classifier with a soft-decision 
method based on a probabilistic Bayesian learning framework and outperformed SVM when tested 





In this manuscript it was attempted an integrated and interdisciplinary approach to the “early” 
diagnosis of Alzheimer disease with the idea to move from the concept of early identification of 
Mild Cognitive Impairment prodromal to AD to the systematic screening of at risk populations in 
view of the possible arrival of disease-modifying drugs.  
During a meeting held in Rome in June 2017 a panel of Experts from different disciplines has 
discussed this problem integrating the various disciplines involved in this field (epidemiology, 
neuropsychology, fluid testing, genetics, neuroimaging both structural and functional, EEG/MEG 
both spontaneous and task-related). Many of them agreed to prepare a common manuscript 
providing a review of the strengths and weaknesses of the individual biomarkers for early diagnosis. 
The International Federation of Clinical Neurophysiology has supported this meeting; such an 
endorsement has been triggered by the “vision” that the neurophysiological methods (in particular 
the advanced analysis of electromagnetic brain signals) could represent a first-line screening tool 
particularly for their for their high sensitivity to synaptic function, non-invasiveness, low-cost and 
widespread availability. Since EEG/MEG digitized signals can be easily translated via a 
technological platform from recording places on the territory to expert’s centers for sophisticated 
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analysis, harmonization of the analysis methods can be and should be accomplished. Needless to 
say, neurophysiological methods alone cannot reach neither the required accuracy nor the 
diagnostic specificity (i.e. distinguish AD from other dementias or amyloid-positive from amyloid-
negative AD forms), but –if combined with other biomarkers with the same characteristics 
(innocuous, low-cost, widely available)- could contribute for a first-line screening that allows for 
defining high-risk subjects currently investigated only with highly sophisticated/expensive (i.e. 
volumetric MRI, PET with radioligands) and invasive (i.e. lumbar puncture) approaches. Given 
100% cases on entry, one could predict to remain with about 15-20% cases for second- and third-
line further evaluation, making the whole scenario affordable both from the organizational and 
financial sides. The literature review presented here indicates several approaches that are extremely 
promising to open a new era in EEG/MEG methods to innovative clinical applications in the field 
of dementia eraly diagnosis with huge implications. Companies are very slow in appreciating this 
opportunity, while researchers from the neuroscientific clinical community seem to be -once again- 
on the frontline.  
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Fig. 1. A) Extended pedigree representing known affected subjects of all families with PS1 
Met146Leu mutation. B) Pedigree of the family with APP A713T mutation associates to both early 
and late onset phenotypes, also independently from homozygosity. 
Fig. 2. The Functional Source Separation (FSS) algorithm is a new concept-source identification 
method with MEG/EEG/EMG, developed by LET’S. To identify the source, FSS exploits a specific 
functional fingerprint of the source neurodynamics -instead of the source’s position-. FSS returns 
the source’s neurodynamics in all experimental conditions of interest, together with the source 
scalp distribution, which is the input for the localization algorithms, if the source’s position is of 
interest. 
Fig. 3. Scheme of an automated EEG-based AD diagnosis system in the cross-validation leave-one-
subject-out paradigm (Cassani et al., 2014). 
 
